Edition:
India

Alnylam Pharmaceuticals Inc (ALNY.OQ)

ALNY.OQ on NASDAQ Stock Exchange Global Select Market

107.47USD
13 Jul 2018
Change (% chg)

$-0.58 (-0.54%)
Prev Close
$108.05
Open
$108.26
Day's High
$108.96
Day's Low
$106.41
Volume
163,182
Avg. Vol
337,865
52-wk High
$153.80
52-wk Low
$70.78

Chart for

About

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs... (more)

Overall

Beta: 2.97
Market Cap(Mil.): $11,251.10
Shares Outstanding(Mil.): 91.73
Dividend: --
Yield (%): --

Financials

BRIEF-Alnylam Reports Preclinical Data Demonstrating Central Nervous System Delivery Of RNAi Therapeutics

* ALNYLAM REPORTS PRECLINICAL DATA DEMONSTRATING CENTRAL NERVOUS SYSTEM (CNS) DELIVERY OF RNAI THERAPEUTICS

08 May 2018

BRIEF-Alnylam Pharmaceuticals Reports Q1 Loss Per Share Of $1.41

* ALNYLAM PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PERIOD ACTIVITY

04 May 2018

BRIEF-Alnylam Achieves Alignment With FDA On Accelerated Development Path For Lumasiran

* ALNYLAM ACHIEVES ALIGNMENT WITH FDA ON ACCELERATED DEVELOPMENT PATH FOR LUMASIRAN, AN INVESTIGATIONAL RNAI THERAPEUTIC FOR THE TREATMENT OF PRIMARY HYPEROXALURIA TYPE 1 (PH1)

03 May 2018

BRIEF-Alnylam Reports New Clinical Results From The Apollo Phase 3 Study Of Patisiran

* ALNYLAM REPORTS NEW CLINICAL RESULTS FROM THE APOLLO PHASE 3 STUDY OF PATISIRAN AT THE AMERICAN ACADEMY OF NEUROLOGY 2018 ANNUAL MEETING

24 Apr 2018

BRIEF-Alnylam Receives Positive Opinion For Orphan Drug Designation In EU For ALN-TTRsc02, For Treatment Of Transthyretin-Mediated Amyloidosis

* ALNYLAM RECEIVES POSITIVE OPINION FOR ORPHAN DRUG DESIGNATION IN THE EUROPEAN UNION FOR ALN-TTRSC02, A SUBCUTANEOUSLY DELIVERED INVESTIGATIONAL RNAI THERAPEUTIC FOR THE TREATMENT OF TRANSTHYRETIN-MEDIATED AMYLOIDOSIS Source text for Eikon: Further company coverage:

23 Apr 2018

U.S. biotech companies Alnylam, Dicerna settle trade secrets case

BOSTON Alnylam Pharmaceuticals Inc said on Friday that Dicerna Pharmaceuticals Inc will pay it $25 million in cash and stock to resolve a lawsuit claiming it stole trade secrets about gene-silencing technology used to develop drug treatments.

20 Apr 2018

U.S. biotech companies Alnylam, Dicerna settle trade secrets case

BOSTON Alnylam Pharmaceuticals Inc said on Friday that Dicerna Pharmaceuticals Inc will pay it $25 million in cash and stock to resolve a lawsuit claiming it stole trade secrets about gene-silencing technology used to develop drug treatments.

20 Apr 2018

UPDATE 2-U.S. biotech companies Alnylam, Dicerna settle trade secrets case

BOSTON, April 20 Alnylam Pharmaceuticals Inc said on Friday that Dicerna Pharmaceuticals Inc will pay it $25 million in cash and stock to resolve a lawsuit claiming it stole trade secrets about gene-silencing technology used to develop drug treatments.

20 Apr 2018

CORRECTED-UPDATE 1-U.S. biotech companies Alnylam, Dicerna settle trade secrets case

BOSTON, April 20 Dicerna Pharmaceuticals Inc on Friday said that it will pay $15 million plus stock to Alnylam Pharmaceuticals Inc to resolve a lawsuit claiming it stole trade secrets about gene-silencing technology used to develop drug treatments.

20 Apr 2018

CORRECTED-Biotech companies Alnylam, Dicerna settle trade secrets case

BOSTON, April 20 Dicerna Pharmaceuticals Inc on Friday said it will pay $15 million plus stock to Alnylam Pharmaceuticals Inc to resolve a lawsuit claiming it stole trade secrets about gene-silencing technology used to develop drug treatments.

20 Apr 2018

Earnings vs. Estimates